7 November 2019

EraCal Therapeutics AG, established as a spin-off from the University of Zurich and Harvard University, completes an oversubscribed seed financing round. Investors included Bernina BioInvest, Redalpine, the UZH Life Sciences Fund and private investors. The seed capital will be used to advance the preclinical development of Era-107, an appetite modulator that has a more specific effect than previous drugs and therefore causes fewer side effects. VISCHER acts as legal advisor to EraCal Therapeutics AG in the seed financing round. The VISCHER team includes Christian Wyss (Partner, Corporate / M&A), Luzius Zumstein (Associate, Corporate / M&A), Dr. Sara Ianni (Associate, Corporate / M&A), and Adrian Briner (Associate, Tax).

Press release

Categories: Life Sciences, Pharma, Biotech, Private Equity & Venture Capital

You are currently offline. Some pages or content may fail to load.